Market Place
Sourcing Support
Kezar’s Autoimmune Drug Faces Second FDA Clinical Hold
13 Nov 2024 //
BIOSPACE
Kezar Life Sciences Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
BUSINESSWIRE
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
28 Oct 2024 //
BUSINESSWIRE
Kezar Cuts Lupus Program, Focuses on Autoimmune Hepatitis
18 Oct 2024 //
BIOSPACE
Kezar Life Sciences Reports Positive Portola Trial Safety Review
17 Oct 2024 //
BUSINESSWIRE
Kezar rejects Concentra buyout that `undervalues` the biotech
17 Oct 2024 //
FIERCE BIOTECH
Concentra Spies New Target After Kezar’s Lupus Trial Hold
10 Oct 2024 //
BIOSPACE
FDA places Kezar lupus trial in hold following 4 patient deaths
07 Oct 2024 //
FIERCE BIOTECH
FDA puts Kezar`s lupus treatment trial on hold after patient deaths
05 Oct 2024 //
REUTERS
Kezar Reports Four Patient Deaths in Mid-Stage Lupus Nephritis Study
02 Oct 2024 //
BIOSPACE
Kezar halts mid-stage lupus study after four deaths
01 Oct 2024 //
FIERCE BIOTECH
Kezar Life Sciences Ends Enrollment In Ph2 Trial For Zetomipzomib
30 Sep 2024 //
BUSINESSWIRE
Kezar drops solid tumor drug that has yet to prove worth in phase 1
14 Aug 2024 //
FIERCE BIOTECH
Kezar Life Sciences Reports Q2 2024 Results And Business Update
13 Aug 2024 //
BUSINESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
10 Jul 2024 //
BUSINESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
07 Jun 2024 //
BUSINESSWIRE
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
29 May 2024 //
BUSINESSWIRE
Kezar Life Sciences Q1 2024 Financials, Business Update
09 May 2024 //
BUSINESSWIRE
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06 May 2024 //
BUSINESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
08 Apr 2024 //
BUSINESSWIRE
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results
14 Mar 2024 //
BUSINESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
08 Mar 2024 //
BUSINESSWIRE
Kezar Life to Participate in the TD Cowen 44th Annual Health Care Conference
28 Feb 2024 //
BUSINESSWIRE
Everest Medicines and Kezar Receive IND Approval from NMPA for PALIZADE Trial
26 Feb 2024 //
BUSINESSWIRE
Kezar Life to Present at the 6th Annual Evercore ISI HealthCONx Conference
21 Nov 2023 //
BUSINESSWIRE
Kezar Life Sciences Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
BUSINESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
03 Nov 2023 //
BUSINESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
09 Oct 2023 //
BUSINESSWIRE
Kezar Life Sciences Announces Strategic Restructuring
03 Oct 2023 //
BUSINESSWIRE
Inventiva, Kezar sell Asian rights to NASH and autoimmune assets
21 Sep 2023 //
FIERCE BIOTECH
Kezar and Everest Medicines Enter into an Agreement to Develop Zetomipzomib
20 Sep 2023 //
BUSINESSWIRE
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
31 Aug 2023 //
BUSINESSWIRE
Kezar Life Sciences Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
BUSINESSWIRE
Kezar Life Sciences to Participate in the Jefferies Healthcare Conference
31 May 2023 //
BUSINESSWIRE
Kezar Life Sciences Reports First Quarter 2023 Financial Results
11 May 2023 //
BUSINESSWIRE
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Apr 2023 //
BUSINESSWIRE
Kezar Life Reports Fourth Quarter and Year End 2022 Financial Results
14 Mar 2023 //
BUSINESSWIRE
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023
13 Mar 2023 //
BUSINESSWIRE
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023
06 Mar 2023 //
BUSINESSWIRE
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 Mar 2023 //
BUSINESSWIRE
Kezar Life to Participate in the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
BUSINESSWIRE
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06 Feb 2023 //
BUSINESSWIRE
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
13 Jan 2023 //
BUSINESSWIRE
Kezar to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
BUSINESSWIRE
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07 Dec 2022 //
BUSINESSWIRE
Kezar Presents Complete Results from Phase 2 Trial Evaluating Zetomipzomib
14 Nov 2022 //
BUSINESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11 Nov 2022 //
BUSINESSWIRE
Kezar Life Sciences Reports 3Q 2022 Financial Results and Provides Update
10 Nov 2022 //
BUSINESSWIRE
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
09 Nov 2022 //
BUSINESSWIRE
Kezar Presents Results from the MISSION PII Trial Evaluating Zetomipzomib
03 Nov 2022 //
BUSINESSWIRE
Kezar to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib
14 Oct 2022 //
BUSINESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
06 Oct 2022 //
BUSINESSWIRE
Kezar to commence Phase IIa autoimmune hepatitis therapy trial
04 Oct 2022 //
CLINICALTRIALSARENA
Kezar Receives FDA Clearance of IND for Zetomipzomib for Autoimmune Hepatitis
03 Oct 2022 //
BUSINESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
02 Sep 2022 //
BUSINESSWIRE
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
01 Sep 2022 //
BUSINESSWIRE
Kezar Life Sciences Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Kezar Life Appoints Nick Mordwinkin as CBO and Reports Updated Cash Position
11 Jul 2022 //
BUSINESSWIRE
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
07 Jul 2022 //
BUSINESSWIRE
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06 Jul 2022 //
BUSINESSWIRE
